Annual report pursuant to Section 13 and 15(d)

Debt - Narrative (Details)

v3.8.0.1
Debt - Narrative (Details)
1 Months Ended 12 Months Ended 48 Months Ended
Dec. 22, 2017
USD ($)
Aug. 07, 2017
USD ($)
Mar. 17, 2017
USD ($)
Feb. 01, 2017
USD ($)
Nov. 05, 2015
USD ($)
Apr. 01, 2015
d
conversion_right
$ / shares
Rate
Jan. 30, 2013
USD ($)
d
Feb. 01, 2017
USD ($)
Jan. 31, 2013
d
$ / shares
Rate
Dec. 31, 2017
USD ($)
institution
$ / shares
Rate
Dec. 31, 2016
USD ($)
institution
$ / shares
Rate
Dec. 31, 2015
USD ($)
$ / shares
Rate
Dec. 31, 2016
USD ($)
institution
$ / shares
shares
Aug. 31, 2015
USD ($)
Aug. 31, 2012
USD ($)
Debt Instrument [Line Items]                              
Gain on embedded derivative               $ 3,200,000              
Embedded conversion option       $ 13,600,000       $ 13,600,000              
Credit line capacity                   $ 197,320,000          
Goodwill                   $ 717,099,000 $ 704,603,000 $ 743,348,000 $ 704,603,000    
Number of financial institutions | institution                   11 10   10    
BioReference Laboratories, Inc.                              
Debt Instrument [Line Items]                              
Net assets                   $ 900,000,000          
Goodwill                   401,800,000       $ 401,821,000  
Intangible assets                   $ 446,500,000       $ 545,250,000  
OPKO Health Europe                              
Debt Instrument [Line Items]                              
Goodwill                             $ 8,062,000
Intangible assets                             $ 8,378,000
Weighted average interest rate                   3.00% 3.20%   3.20%    
Minimum | OPKO Health Europe                              
Debt Instrument [Line Items]                              
Variable interest rates                   1.80%          
Maximum | OPKO Health Europe                              
Debt Instrument [Line Items]                              
Variable interest rates                   6.30%          
Notes | Notes Due February 1, 2033                              
Debt Instrument [Line Items]                              
Debt face amount             $ 175,000,000.0                
Interest rate of notes payable             3.00%     3.00% 3.00% 3.00% 3.00%    
Equivalent redemption price                 100.00%            
Conversion rate | Rate           14.14827%     14.14827% 14.14827% 14.14827% 14.14827%      
Conversion price (in dollars per share) | $ / shares           $ 7.07     $ 7.07 $ 7.07 $ 7.07 $ 7.07 $ 7.07    
Convertible debt, threshold percentage of stock price trigger           130.00%     130.00%            
Threshold trading days | d           20                  
Number of consecutive trading days applicable conversion price | d           30                  
Common stock trigger price (in dollars per share) | $ / shares           $ 9.19                  
Conversion rights triggered | conversion_right           1                  
Estimated credit spread | Rate                   7.61% 7.65% 11.42%      
Notes | Notes Due February 1, 2033 | Minimum                              
Debt Instrument [Line Items]                              
Threshold trading days | d             20                
Notes | Notes Due February 1, 2033 | Maximum                              
Debt Instrument [Line Items]                              
Number of consecutive trading days applicable conversion price | d                 30            
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019                              
Debt Instrument [Line Items]                              
Equivalent redemption price                 100.00%            
Convertible Debt | Notes Due February 1, 2033                              
Debt Instrument [Line Items]                              
Convertible notes, conversion                         $ 143,200,000    
Line of Credit                              
Debt Instrument [Line Items]                              
Weighted average interest rate                   4.20% 4.70%   4.70%    
Common stock investments, available for sale | Convertible Debt | Notes Due February 1, 2033                              
Debt Instrument [Line Items]                              
Convertible debt, stock issued from conversion (in shares) | shares                         21,539,873    
Revolving Credit Facility | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Credit line capacity         $ 175,000,000.0                    
Higher borrowing capacity option         $ 275,000,000.0                    
Total availability under credit agreement                   $ 104,200,000          
Commitment fee percentage         0.50%                    
Intercompany loan maximum borrowing capacity $ 45,000,000.0 $ 35,000,000 $ 55,000,000                        
Bridge Loan | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Credit line capacity         $ 20,000,000.0                    
Letter of Credit | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Credit line capacity         $ 20,000,000.0                    
LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Estimated credit spread         2.50%                    
LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Estimated credit spread         0.35%                    
LIBOR, thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Estimated credit spread         0.50%                    
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Estimated credit spread         1.35%                    
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                              
Debt Instrument [Line Items]                              
Estimated credit spread         1.50%                    
Additional Paid-In Capital                              
Debt Instrument [Line Items]                              
Embedded conversion option, conversion       $ 13,600,000